Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 11:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,535 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Perioperative Opioid Sparing Techniques
Interventions
Intrathecal Morphine Block, Bilateral Quadratus Lumborum Block, Bilateral Transverse Abdominis Plane Block
Procedure
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
Interventions
Labetuzumab Govitecan (LG)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
Santa Monica, California • Aurora, Colorado • Newark, Delaware + 4 more
Conditions
Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Colorectal Cancer, Sarcomas, Metastatic Prostate Cancer, Ovarian Cancer, Small Cell Lung Cancer, Metastatic Breast Cancer, Pancreas Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Cervical Cancer, Adenoid Cystic Carcinoma, Salivary Gland Cancer, Urothelial Carcinoma
Interventions
ONC-392, Pembrolizumab, Docetaxel
Drug
Lead sponsor
OncoC4, Inc.
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
33
States / cities
Springdale, Arkansas • Davis, California • Downey, California + 27 more
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Leucovorin, Irinotecan
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Houston, Texas
Conditions
Metastatic Colorectal Cancer
Interventions
OSI-906, Everolimus
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Fort Myers, Florida • Nashville, Tennessee
Conditions
Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
MRG007, MRG007 and Bevacizumab
Drug
Lead sponsor
ArriVent BioPharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Conditions
Breast Cancer, Cardiovascular Complications, Colorectal Cancer, Fallopian Tube Cancer, Head and Neck Cancer, Lung Cancer, Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, questionnaire administration
Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Nashville, Tennessee
Conditions
Colon Cancer, Rectal Cancer, Cancer Survivor, Colorectal Adenocarcinoma, Stage I Colorectal Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8
Interventions
Dietary Intervention (resistant starch), Dietary Intervention (regular starch), Questionnaire Administration
Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
Irinotecan
Drug
Lead sponsor
Reema A. Patel
Other
Eligibility
18 Years and older
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
Advanced Colorectal Cancer
Interventions
PM060184
Drug
Lead sponsor
PharmaMar
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
Interventions
enzastaurin, irinotecan, cetuximab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Casa Grande, Arizona • Tucson, Arizona • Los Angeles, California + 17 more
Conditions
Colorectal Cancer
Interventions
gefitinib
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
16
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 9 more
Conditions
Colorectal Neoplasms
Interventions
KD018, Irinotecan, Placebo
Drug
Lead sponsor
Edward Chu, MD
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
2
States / cities
New Haven, Connecticut • Pittsburgh, Pennsylvania
Conditions
Pancreatic Cancer, Colorectal Cancer (CRC), Breast Cancer, Lung Cancer
Interventions
Ruxolitinib, Capecitabine, Regorafenib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
6
States / cities
Santa Monica, California • Louisville, Kentucky • Clifton Park, New York + 3 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

Navigation From Community to Clinic to Promote CRC Screening in Underserved Populations

NCT01853774
Conditions
Colorectal Cancer
Interventions
Tailored navigation
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
50 Years to 75 Years
Enrollment
419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Phoenix, Arizona
Conditions
Melanoma, Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Renal Cancer, Head and Neck Cancer, Other Solid Cancers
Interventions
Autogene cevumeran, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 10 more
Conditions
Colorectal Cancer
Interventions
Oral Tablet: Cabozantinib
Drug
Lead sponsor
Academic Thoracic Oncology Medical Investigators Consortium
Industry
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 6 more
Conditions
Colorectal Cancer, Colon Polyps, Adenomatous Polyp of Colon
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 49 Years
Enrollment
1,623 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2014
U.S. locations
6
States / cities
Bethesda, Maryland • Ann Arbor, Michigan • Detroit, Michigan + 2 more
Conditions
Metastatic Colorectal Cancer
Interventions
NIS793, Bevacizumab, Modified FOLFOX6, FOLFIRI, Tislelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Ann Arbor, Michigan • St Louis, Missouri + 4 more
Conditions
Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Rectal Cancer AJCC v8, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma
Interventions
Cetuximab, Encorafenib, Nivolumab
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
282
States / cities
Goodyear, Arizona • Carmichael, California • Dublin, California + 223 more
Conditions
Metastatic Colorectal Cancer
Interventions
TF2/IMP288
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Colorectal Cancer
Interventions
Intervention Arm
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
45 Years to 49 Years
Enrollment
7,120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Darizmetinib, Embolization Therapy, Hepatectomy, Magnetic Resonance Imaging, Placebo Administration, Positron Emission Tomography
Procedure · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Mucinous Adenocarcinoma of the Colon, Mucinous Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Signet Ring Adenocarcinoma of the Colon, Signet Ring Adenocarcinoma of the Rectum, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan hydrochloride, oxaliplatin, leucovorin calcium, fluorouracil, quality-of-life assessment
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Rochester, Minnesota